Skip to main content
Premium Trial:

Request an Annual Quote

Certara Repeats Bid to Acquire Symyx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Certara today issued a letter to Symyx's board revising its offer to acquire the company and removing any doubt that its offer provides certainty of closure.

In its letter, Certara confirms its bid of $5.75 per share in cash originally made to Symyx last week. In addition, Certara said the offer is irrevocable and effective immediately; "empowers the Symyx [board] to accept the offer and legally bind Certara once the Accelrys merger has been terminated;" is contained in a signed merger agreement; and is guaranteed by Vector Capital, Certara's private equity backer.

The revised offer "should remove any doubt in the minds of you or the Symyx stockholders that our proposal provides certainty of closure," Certara said in the letter.

Earlier this week, Symyx rejected Certara's offer, saying it did not represent a superior offer to an earlier bid by Accelerys. Symyx also said that Certara's offer does not provide "sufficient certainty to closure necessary to protect Symyx stockholders."

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.